Discover More About Our Treatments for Neurological Diseases


  • Bethlehem, PA, December 19, 2019

    Ophidion, Inc. closes Series Seed round for a total of $1.7M led by Robin Hood Ventures: Philadelphia-based angel investor group Robin Hood Ventures (RHV) announced an initial investment in Ophidion Inc., a Pennsylvania-based private biotechnology company. Ophidion Inc has a platform technology that acts as a Trojan horse to shuttle various cargoes across the blood-brain barrier following intravenous administration. The company is currently focused on developing a pipeline to deliver gene silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease). This seed series will be used to advance the Huntington’s program through preclinical proof of concept, which would de-risk the entire platform as well as position the Huntington’s program to start the IND-enabling studies. In addition to Robin Hood Ventures, four other groups invested in Ophidion Inc. during this seed round. Those groups were: Ben Franklin Technology Partners, Delaware Crossing Investor Group, Viva Incubator Investment Management Limited, and Gaingels.

  • Bethlehem, PA, June 1, 2018

    Ophidion, Inc., a biotechnology company advancing innovative gene silencing therapeutics for the treatment of brain diseases, has hired Yacoub Habib, Ph.D./MBA as its chief executive officer.

  • Bethlehem, PA, May 15th, 2018

    Ophidion, Inc., a biotechnology company advancing innovative gene silencing therapeutics for the treatment of brain diseases, announced today that it is a recipient of the latest investment cycle of the Ben Franklin Technology Partners of Northeastern Pennsylvania (BFTP/NEP) network regional economic development investment program.
    The BFTP/NEP investment was for $100,000 to support a definitive preclinical study to optimize the delivery of central nervous system therapeutics to targeted sites in the brain. Ophidion is leveraging its proprietary blood-brain-barrier transport technology to advance a systemically delivered gene-silencing siRNA product for the treatment of Huntington’s disease, a fatal neurodegenerative disease with no current cure.
    The Ben Franklin Technology Partners’ Board of Directors made investments totaling $695,000 in this cycle in support of regional early-stage companies. These investments are provided in the form of loans with warrants. BFTP/NEP’s goal is to help lead northeastern Pennsylvania to a better economic future by building partnerships that develop and apply technology for competitive advantage.

Contact Us

This field is for validation purposes and should be left unchanged.